DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

0.81USD-0.03 (-3.57%)Delayed

Market Summary

USD0.81-0.03

Delayed

-3.57%

DNA Alerts

1 major insider sales recently.

Big fall in Revenue (Y/Y)

DNA Stock Price

View Fullscreen

DNA RSI Chart

DNA Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-1.84

Price/Sales (Trailing)

7.89

EV/EBITDA

-0.96

Price/Free Cashflow

-5.11

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-409.17%

Return on Equity

-90.44%

Return on Assets

-56.45%

Free Cashflow Yield

-19.56%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

208.7M

Rev. Growth (Yr)

-52.98%

Rev. Growth (Qtr)

9.18%

DNA Earnings

Earnings (TTM)

-892.9M

Earnings Growth (Yr)

-20.65%

Earnings Growth (Qtr)

30.11%

Breaking Down DNA Revenue

Last 7 days

6.6%

Last 30 days

-6.9%

Last 90 days

-44.9%

Trailing 12 Months

-38.6%

How does DNA drawdown profile look like?

DNA Financial Health

Current Ratio

5.34

DNA Investor Care

Shares Dilution (1Y)

6.20%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	208.7M	0	0	0
2023	390.0M	326.0M	315.0M	251.5M
2022	438.1M	539.1M	527.9M	477.7M
2021	136.0M	195.2M	254.5M	313.8M
2020	0	0	65.4M	76.7M
2019	0	0	0	54.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ginkgo Bioworks Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	coen steven p.	sold	-111,479	0.845	-131,928	see remarks
May 02, 2024	dmytruk mark e.	sold	-40,396	0.845	-47,806	see remarks
May 01, 2024	coen steven p.	acquired	-	-	294,455	see remarks
May 01, 2024	dmytruk mark e.	acquired	-	-	108,127	see remarks
Apr 02, 2024	dmytruk mark e.	sold	-53,727	1.05	-51,169	see remarks
Apr 01, 2024	dmytruk mark e.	acquired	-	-	108,123	see remarks
Mar 04, 2024	dmytruk mark e.	sold	-48,765	1.256	-38,826	see remarks
Mar 01, 2024	dmytruk mark e.	acquired	-	-	85,214	see remarks
Feb 02, 2024	dmytruk mark e.	sold	-47,799	1.208	-39,569	see remarks
Feb 01, 2024	dmytruk mark e.	acquired	-	-	85,208	see remarks

Which funds bought or sold DNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-43.32	-3,769,820	2,400,700	-%
May 16, 2024	COMERICA BANK	added	6.44	-14,047	38,090	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-2,125	-	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	reduced	-38.94	-110,899	209,603	0.01%
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-42,135	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-6.66	-719,667	1,283,120	-%
May 15, 2024	Cetera Advisors LLC	added	12.13	-121,008	404,310	-%
May 15, 2024	Gotham Asset Management, LLC	reduced	-95.79	-2,217,100	65,970	-%
May 15, 2024	Laird Norton Wetherby Wealth Management, LLC	added	31.53	-1,845	17,131	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.04	-305,492	685,206	-%

Are Funds Buying or Selling DNA?

Are funds buying DNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNA

No. of Funds

Unveiling Ginkgo Bioworks Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	knight thomas f. jr.	4.1%	68,328,434	SC 13G/A
Feb 14, 2024	che austin	5.6%	95,898,483	SC 13G/A
Feb 14, 2024	shetty reshma p.	10.5%	188,643,922	SC 13D/A
Feb 14, 2024	kelly jason r	5.0%	85,752,333	SC 13D/A
Feb 14, 2024	viking global investors lp	8.8%	143,085,126	SC 13G/A
Feb 13, 2024	vanguard group inc	8.20%	132,779,676	SC 13G/A
Jan 29, 2024	ark investment management llc	12.26%	198,606,619	SC 13G/A
Jan 29, 2024	baillie gifford & co	14.59%	236,292,183	SC 13G/A
Feb 14, 2023	anchorage capital group, l.l.c.	4.83%	69,904,593	SC 13G/A
Feb 14, 2023	che austin	6.3%	99,857,282	SC 13G/A

Recent SEC filings of Ginkgo Bioworks Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	424B3	Prospectus Filed
May 17, 2024	144	Notice of Insider Sale Intent
May 16, 2024	4	Insider Trading
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 15, 2024	144	Notice of Insider Sale Intent
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 14, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Ginkgo Bioworks Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ginkgo Bioworks Holdings, Inc. News

Latest updates

Ginkgo Bioworks Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	9.2%	37,944,000	34,755,000	55,430,000	80,568,000	80,702,000	98,285,000	66,398,000	144,618,000	168,405,000	148,494,000	77,610,000	43,636,000	44,097,000	28,699,500	13,302,000	-
Operating Expenses	1.4%	215,946,000	212,872,000	341,823,000	264,719,000	296,447,000	329,149,000	721,336,000	792,397,000	843,776,000	1,833,229,000	104,282,000	103,581,000	101,212,000	-	47,715,000	-
S&GA Expenses	-100.0%	-	89,223,000	82,028,000	102,341,000	111,433,000	121,383,000	435,221,000	438,427,000	434,768,000	781,626,000	28,959,000	34,440,000	17,927,000	5,000	9,876,000	-
R&D Expenses	-	136,457,000	-	156,662,000	144,282,000	162,639,000	177,548,000	261,460,000	290,059,000	323,576,000	985,025,000	53,021,000	52,031,000	59,585,000	-	36,070,000	-
EBITDA Margin	-16.1%	-3.80	-3.27	-2.41	-3.52	-4.27	-4.35	-6.61	-5.44	-5.30	-5.76	-0.43	-0.56	-0.80	-1.42	-1.63	-1.97
Interest Expenses	126.7%	11,711,000	-43,821,000	15,020,000	14,349,000	14,545,000	-8,538,000	6,380,000	2,264,000	-177,000	3,854,000	-528,000	-478,000	-475,000	-	8,293,000	-
Income Taxes	115.7%	31,000	-198,000	-22,000	67,000	82,000	-14,770,000	-28,000	-45,000	-184,000	-683,000	-207,000	-431,000	-159,000	-	6,000	-
Earnings Before Taxes	21.7%	-165,880,000	-211,892,000	-302,913,000	-173,248,000	-204,887,000	-187,848,000	-670,159,000	-670,615,000	-592,777,000	-1,605,678,000	-102,612,000	-54,895,000	-74,937,000	-	-26,120,000	-
EBT Margin	-15.2%	-4.09	-3.55	-2.76	-3.79	-4.44	-4.44	-6.70	-5.51	-5.38	-5.86	-0.49	-0.64	-0.92	-1.63	-1.83	-2.21
Net Income	100.0%	-	-211,694,000	-302,891,000	-173,315,000	-204,969,000	-175,468,000	-670,131,000	-668,825,000	-590,505,000	-1,600,656,000	-101,881,000	-53,941,000	-73,569,000	-5,000	-26,055,000	-
Net Income Margin	-20.5%	-4.28	-3.55	-2.72	-3.75	-4.41	-4.41	-6.69	-5.49	-5.36	-5.83	-0.90	-0.79	-0.94	-1.05	-1.82	-2.20
Free Cashflow	-56.6%	-95,969,000	-61,277,000	-77,932,000	-87,066,000	-110,026,000	-130,176,000	-41,834,000	-108,981,000	-23,478,000	-170,655,000	-10,673,000	-58,945,000	-70,066,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-5.0%	1,582	1,665	2,026	2,292	2,417	2,539	1,871	1,994	2,058	2,071	2,151	1,726	1,728	675	697
Current Assets	-9.9%	903	1,002	1,142	1,223	1,327	1,450	1,462	1,599	1,706	1,723	1,811	1.00	3.00	427	512
Cash Equivalents	-6.0%	887	944	1,049	1,106	1,206	1,316	1,303	1,377	1,493	1,550	1,739	236	308	381	495
Inventory	-	-	-	0.00	0.00	3.00	4.00	6.00	8.00	9.00	3.00	3.00	-	-	3.00	-
Net PPE	4.1%	196	188	202	294	314	315	188	176	149	146	143	-	-	121	63.00
Goodwill	-2.7%	48.00	49.00	58.00	59.00	59.00	60.00	29.00	31.00	21.00	21.00	17.00	-	-	2.00	2.00
Liabilities	4.6%	594	568	774	788	810	803	431	427	444	504	533	255	150	205	195
Current Liabilities	3.2%	169	164	168	163	192	173	125	135	159	135	90.00	5.00	1.00	73.00	40.00
Shareholder's Equity	-10.0%	987	1,097	1,253	1,504	1,608	1,736	1,444	1,572	1,619	1,567	1,618	356	396	470	502
Retained Earnings	-3.1%	-5,456	-5,290	-5,078	-4,775	-4,602	-4,397	-4,222	-3,557	-2,888	-2,297	-697	-101	5.00	-467	-341
Additional Paid-In Capital	0.9%	6,445	6,386	6,334	6,281	6,212	6,136	5,669	5,098	4,471	3,805	2,250	106	-	929	-
Shares Outstanding	1.6%	2,034	2,001	1,973	1,924	1,915	1,892	1,631	1,621	1,607	1,360	1,302	1,291	1,290	1,275	1,149
Minority Interest	-	-	-	-	-	-	-	5.00	32.00	33.00	62.00	66.00	-	-	9.00	9.00
Float	-	-	-	-	2,433	-	-	-	2,392	-	-	-	251	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-54.3%	-89.26	-57.83	-73.55	-73.53	-90.58	-104	-28.36	-99.41	-19.90	-165	-5.23	-34.91	-48.13	-	-	-
Share Based Compensation	-4.8%	41.00	43.00	53.00	61.00	73.00	108	563	607	653	-	0.00	15.00	0.00	-	-	-
Cashflow From Investing	74.1%	-12.11	-46.67	-3.38	-11.22	-19.41	30.00	-46.49	-14.66	-35.98	4.00	-30.51	-23.93	-23.05	-	-	-
Cashflow From Financing	-33.7%	-0.84	-0.63	-0.31	-1.38	-0.89	98.00	-0.39	-0.84	-1.19	-11.04	1,548	-2.12	-0.43	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	25.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DNA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Total revenue

$ 37,944

$ 80,702

Costs and operating expenses:

Research and development

136,457

162,639

General and administrative

70,287

111,433

Total operating expenses

215,946

296,447

Loss from operations

(178,002)

(215,745)

Other income (expense):

Interest income, net

11,711

14,545

Loss on equity method investments

(1,449)

Loss on investments

(2,544)

(6,370)

Change in fair value of warrant liabilities

940

1,204

Other income, net

2,015

2,928

Total other income (expense)

12,122

10,858

Loss before income taxes

(165,880)

(204,887)

Income tax expense

Net loss

$ (165,911)

$ (204,969)

Net loss per share, basic (in dollars per share)

$ (0.08)

$ (0.11)

Net loss per share, diluted (in dollars per share)

$ (0.08)

$ (0.11)

Weighted average common shares outstanding:

Basic (in shares)

2,004,460,000

1,914,963,000

Diluted (in shares)

2,005,336,000

1,916,637,000

Comprehensive loss:

Net loss

$ (165,911)

$ (204,969)

Other comprehensive (loss) income:

Foreign currency translation adjustment

(3,035)

1,018

Total other comprehensive (loss) income

(3,035)

1,018

Comprehensive loss

(168,946)

(203,951)

Cell Engineering

Total revenue

^[1]

27,889

34,096

Product

Total revenue

11,666

Costs and operating expenses:

Cost of Biosecurity revenue

4,541

Service

Total revenue

10,055

34,940

Costs and operating expenses:

Cost of Biosecurity revenue

$ 9,202

$ 17,834

[1]	Includes related party revenue of $733 and $4,703 for the three months ended March 31, 2024 and 2023, respectively.

DNA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 840,440	$ 944,073
Accounts receivable, net	24,189	17,157
Accounts receivable - related parties	370	742
Prepaid expenses and other current assets	38,021	39,777
Total current assets	903,020	1,001,749
Property, plant, and equipment, net	195,992	188,193
Operating lease right-of-use assets	220,785	206,801
Investments	76,021	78,565
Intangible assets, net	77,407	82,741
Goodwill	47,909	49,238
Other non-current assets	60,627	58,055
Total assets	1,581,761	1,665,342
Current liabilities:
Accounts payable	26,995	9,323
Deferred revenue (includes $707 and $5,426 from related parties)	33,612	44,486
Accrued expenses and other current liabilities	108,436	110,051
Total current liabilities	169,043	163,860
Non-current liabilities:
Deferred revenue, net of current portion (includes $123,549 and $119,053 from related parties)	166,067	158,062
Operating lease liabilities, non-current	234,497	221,835
Other non-current liabilities	24,884	24,433
Total liabilities	594,491	568,190
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value (Note 6)	202	199
Additional paid-in capital	6,445,058	6,385,997
Accumulated deficit	(5,456,439)	(5,290,528)
Accumulated other comprehensive (loss) income	(1,551)	1,484
Total stockholders’ equity	987,270	1,097,152
Total liabilities and stockholders’ equity	$ 1,581,761	$ 1,665,342

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO	Dr. Jason Kelly
WEBSITE	ginkgobioworks.com
INDUSTRY	Biotechnology
EMPLOYEES	1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.? What does DNA stand for in stocks?

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ginkgo Bioworks Holdings, Inc. (DNA)?

As of Fri May 17 2024, market cap of Ginkgo Bioworks Holdings, Inc. is 1.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers. The fair value of Ginkgo Bioworks Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ginkgo Bioworks Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ginkgo Bioworks Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

What is Ginkgo Bioworks Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DNA's PE ratio (Price to Earnings) is -1.84 and Price to Sales (PS) ratio is 7.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.